Dallas, Texas 07/22/2013 (Financialstrend) – There had recently been a declining trend in the share prices of Affymetrix, Inc. (NASDAQ:AFFX) for the past few trading sessions. With the conference call to announce the second quarter financial results scheduled on July 31, 2013 this recent declining trend has sent signals of worry to the investors. Affymetrix had recently worked in collaboration with Biodiscovery and had thereby announced that Nexus would further be available for OncoScan Software in order to facilitate the analysis of copy number data related to whole genome.
In the recent years, it had really been difficult for the cancer researchers to obtain the complete and high quality number data with the use of limited DNA samples available from the patients. This recent development made by the two partners, Affymetrix and Biodiscovery had proved to be a significant milestone achievement in the researches related to the field of oncology. Since this innovation, the shares of AFFX had been moving upward presenting significant returns to the investors. However this surge in prices seems to have ended by the middle of the previous week from when on the stock had lost almost 20% in the share prices to decline to the recent levels.
The stock had moved down to lose by 5.54% to close at $4.09 on Friday, after the opening price at $4.36 per share. Affymetrix, Inc. (NASDAQ:AFFX) had throughout the trading session moved between $4.07 and $4.37 per share and presently has 52 week lowest price at $2.96 and 52 week highest price at $5.26 per share. The market cap of the stock is at $290.79 million with 71.10 million shares outstanding and 108% institutional ownership of capital. The trading volume on Friday was at 12.91 million shares on the stock and the average level is at 1.21 million shares per day.
